Drug product
Valsartan and Hydrochlorothiazide tablets USP 160mg/12.5 mg, 90-count bottle, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ 08810. NDC 65862-548-90.
D-0366-2019
Product summary
- Event
- Event 81887
- Status
- Ongoing
- Classification
- Class II
- Quantity
- 92,616 bottles
- Official record key
drug-enforcement:D-0366-2019
Official wording
Reason: CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Code information: Lot # HTSA17033-A, exp. date 10/2020 Lot # HTSA17034-A, exp. date 10/2020 Lot # HTSA17035-A, exp. date 10/2020 Lot # HTSA17036-A, exp. date 10/2020 Lot # HTSA17040-A, exp. date 10/2020 Lot # HTSA17041-A, exp. date 11/2020 Lot # HTSA17042-A, exp. date 11/2020 Lot # HTSA17043-A, exp. date 11/2020 Lot # HTSA17037-A, exp. date 10/2020 Lot # HTSA17039-A, exp. date 10/2020
Distribution pattern: Product was distributed to 25 distributors and Retail Chains who may have further distributed the product throughout the United States.
Derived failure modes
-
Foreign material or chemical contamination
impurity, N-nitrosodimethylamine (NDEA
-
Manufacturing or process control
CGMP Deviations